You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

77 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell, 
Small Cell
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Nov 2023
Regimen
Cancer Type:
Lung, 
Neuroendocrine (Lung)
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
Nov 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Adjuvant, Curative
Dec 2025
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Dec 2025
Drug
Other Name(s): Verzenio®
Updated
Dec 2025
Regimen
Intent: Palliative
Dec 2025
Drug
Other Name(s): Calquence®
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), based on criteria
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours
Intent: Palliative
Funding:
Exceptional Access Program
    ripretinib - For adult patients with advanced gastrointestinal stromal tumours (GIST) who have progression on or intolerance to imatinib, sunitinib and regorafenib
Dec 2025

Pages